Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes

Overview

Journal J Clin Med

Specialty General Medicine

Date 2025 Feb 13

PMID 39941606

Authors

Nur Olgun

Mehmet Emin Arayici

Deniz Kizmazoglu

Refik Emre Cecen

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a highly aggressive pediatric cancer, particularly in children with refractory or relapsed disease, where survival outcomes remain poor despite advancements in treatment. Combining anti-GD2 antibodies, such as dinutixumab beta, dinutixumab, and naxitanab, with conventional chemotherapy has emerged as a promising approach to improve clinical outcomes in this high-risk population. This chemo-immunotherapy regimen meta-analysis aimed to investigate the efficacy of these combination regimens by analyzing objective response rate (ORR), overall survival (OS), and event-free survival (EFS) outcomes across multiple studies. A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Scopus databases were searched, yielding studies comprising the related reports. Both randomized controlled trials and non-randomized studies were included. The primary outcome of interest was ORR, and the secondary outcome of interest was EFS. A random-effects model using the DerSimonian-Laird method and Knapp-Hartung-Sidik-Jonkman adjustments was employed to pool effect sizes, and heterogeneity was assessed using I statistics. A total of ten reports from eight studies were deemed eligible and included in the meta-analysis. The pooled ORR across the studies was 0.45 (95% CI: 0.35-0.54, < 0.001), indicating that approximately 45% of patients showed a favorable treatment response, with moderate heterogeneity (I = 52.78%). The pooled analysis showed an OS of 75% (95% CI: 53-96, < 0.001), and the pooled EFS effect size was 0.59 (95% CI: 0.45-0.73, < 0.001), despite substantial heterogeneity (I = 60.54%). anti-GD2 antibodies combined with conventional chemotherapy may significantly improve response rates and event-free survival in children with refractory or relapsed neuroblastoma. Future research should focus on identifying predictive biomarkers to tailor therapies to individual patients, enhancing both efficacy and safety in this vulnerable population.

References

Talleur A, Triplett B, Federico S, Mamcarz E, Janssen W, Wu J . Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2,.... Biol Blood Marrow Transplant. 2017; 23(11):1910-1917. PMC: 5682204. DOI: 10.1016/j.bbmt.2017.07.011. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Olgun H, Arayici M, Cecen R, Basbinar Y, Ellidokuz H . The association between birth weight and the risk of neuroblastoma: a meta-analysis of observational studies involving 4,361,141 participants. Am J Cancer Res. 2023; 13(9):3854-3863. PMC: 10560925. View

Blom T, Lurvink R, Aleven L, Mensink M, Wolfs T, Dierselhuis M . Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Front Oncol. 2021; 10:601076. PMC: 7925836. DOI: 10.3389/fonc.2020.601076. View

Bava L, Johns A, Kayser K, Freyer D . Cognitive outcomes among Latino survivors of childhood acute lymphoblastic leukemia and lymphoma: A cross-sectional cohort study using culturally competent, performance-based assessment. Pediatr Blood Cancer. 2017; 65(2). PMC: 7521146. DOI: 10.1002/pbc.26844. View

Cheung N, Dyer M . Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013; 13(6):397-411. PMC: 4386662. DOI: 10.1038/nrc3526. View

Mody R, Yu A, Naranjo A, Zhang F, London W, Shulkin B . Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol. 2020; 38(19):2160-2169. PMC: 7325366. DOI: 10.1200/JCO.20.00203. View

London W, Castel V, Monclair T, Ambros P, Pearson A, Cohn S . Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011; 29(24):3286-92. PMC: 3158599. DOI: 10.1200/JCO.2010.34.3392. View

Raiser P, Schleiermacher G, Gambart M, Dumont B, Defachelles A, Thebaud E . Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?. Eur J Cancer. 2024; 202:114001. DOI: 10.1016/j.ejca.2024.114001. View

10.

Bagatell R, London W, Wagner L, Voss S, Stewart C, Maris J . Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010; 29(2):208-13. PMC: 3058276. DOI: 10.1200/JCO.2010.31.7107. View

11.

Schwab M, Westermann F, Hero B, Berthold F . Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003; 4(8):472-80. DOI: 10.1016/s1470-2045(03)01166-5. View

12.

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

13.

Takita J . Molecular Basis and Clinical Features of Neuroblastoma. JMA J. 2021; 4(4):321-331. PMC: 8580727. DOI: 10.31662/jmaj.2021-0077. View

14.

Mody R, Naranjo A, Van Ryn C, Yu A, London W, Shulkin B . Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017; 18(7):946-957. PMC: 5527694. DOI: 10.1016/S1470-2045(17)30355-8. View

15.

Park J, Villablanca J, Hero B, Kushner B, Wheatley K, Beiske K . Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer. 2022; 128(21):3775-3783. PMC: 9614386. DOI: 10.1002/cncr.34445. View

16.

Goddard K . Metabolic syndrome, the risk of cardiovascular disease, physical activity and childhood cancer survivors (Commentry on Slater et al.). Pediatr Blood Cancer. 2014; 62(2):188-189. DOI: 10.1002/pbc.25321. View

17.

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

18.

Bresler S, Weiser D, Huwe P, Park J, Krytska K, Ryles H . ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014; 26(5):682-94. PMC: 4269829. DOI: 10.1016/j.ccell.2014.09.019. View

19.

Matthay K, Maris J, Schleiermacher G, Nakagawara A, Mackall C, Diller L . Neuroblastoma. Nat Rev Dis Primers. 2016; 2:16078. DOI: 10.1038/nrdp.2016.78. View

20.

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View